Quick Takeaways
- Sandra Milligan has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $940,049.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Sandra Milligan
- Location
- San Diego, CA
- Summary
- The estimated net worth of Sandra Milligan is at least $940,049 dollars as of 20 Aug 2025. Sandra Milligan is the Head of Research & Development of Organon & Co. and owns shares of Organon & Co. (OGN) stock worth about $723K. Sandra Milligan is the Director of Gossamer Bio, Inc. and owns shares of Gossamer Bio, Inc. (GOSS) stock worth about $111.5K. Sandra Milligan is the Interim CEO of Aspira Women's Health Inc. and owns shares of Aspira Women's Health Inc. (AWHL) stock worth about $105.6K.
- Signature
- /s/ Jeff Boerneke, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Sandra Milligan and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Organon & Co. ($723,042).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Sandra Milligan
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| OGN | Organon & Co. | Head of Research & Development | $723,042 | 04 May 2023 | ||
| GOSS | Gossamer Bio, Inc. | Director | $111,456 | +$50,016 | +81% | 19 Aug 2025 |
| AWHL | Aspira Women's Health Inc. | Interim CEO | $105,551 | 31 Dec 2024 | ||
| SYRE | Spyre Therapeutics, Inc. | Director | 29 May 2025 |
Insider Transactions Reported by Sandra Milligan:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.